• Head of Discovery Research• Head of Translational Science

◦ Head of Discovery Research, encompassing 3 teams (Bioinformatics, Gene Circuit Research, Cell Therapy Research)◦ Lead discovery and technology development within Senti Bio's cell therapy pipeline◦ Oversee strategic early pipeline planning, with direct oversight of multiple CAR cell therapy programs from target identification through to DC Selection and IND-enabling studies◦ Lead cross-functional collaborations to develop Senti Bio’s allogeneic CAR-NK cell platform and pipeline programs◦ Lead external collaborations to further Senti's technology development◦ Forecast and maintain the Discovery Research departmental budget, and collaboratively help manage the broader R&D budget◦ Inform and confer with Senti leadership on status of pipeline programs, challenges, and potential solutions◦ Successfully completed SBIR contract, receiving highest marks◦ Engage, promote, and educate the scientific community about Senti Bio's innovative technologies, often including multiple conference presentation per year◦ Dedicated to providing a positive and supportive work environment that follows Senti Bio's core values: Be Bold! Better Together! Build to Last!

◦ Head of logic gated CAR-NK cell program for AML◦ Successfully led Senti's first CAR-NK cell program to DC Selection◦ PI on SBIR contract from the NCI for clinical translation of CAR NK cell program◦ Align and support other research teams to ensure fulfillment of R&D and corporate goals

◦ Head of logic gated CAR-NK cell program for AML◦ Enhanced collaborative team efforts through improved communication and deconstructing of informational silos◦ Successfully led Senti's first CAR-NK cell program through lead selection, which required significant novel technology development for both the activating and inhibitory CARs

◦ Led Senti's first CAR T cell therapy team, for the treatment of AML◦ Successfully led efforts to identify the ideal tumor target antigen pair for a bivalent activating CAR approach for logic gated T/NK cell AML programs◦ Successfully led efforts to identify the ideal inhibitory CAR target for protection of healthy cells from on-target off-tumor toxicity within logic gated CAR T/NK cell AML programs

◦ Led a team responsible for identifying and optimizing new cell therapy technologies for Senti Bio

◦ Developed Senti Bio's first cell platform for the design, testing, and development of new gene circuit technologies (PMID: 34210826; co-author)

• Generated and comparatively analyzed transcriptomics data to identify hematopoietic stem cell (HSC)-specific transcription factors, which were then characterized using a variety of in vitro and in vivo functional assays (PMID: 24319662; co-first author)• Identified the transcription factor Zfp521 as a regulator of HSC pool size and MLL-AF9-mediated leukemic disease (PMID: 28615219; co-first author)• Identified Hlf as a key HSC regulator by demonstrating it could imbue progenitors with stem cell-like attributes• In collaboration with Dr. Timothy Springer laboratory, generated bone marrow-derived microglia for successful therapeutic treatment of a neurological disease caused by defective TGFβ signaling (PMID: 29909984; co-first author)• Utilized HSC transcription factor expertise in collaboration to reprogram hematopoietic cells to a stem cell fate (PMID: 24766805; co-author)• Utilized my HSC and microglia experience in collaboration to achieve engraftment of microglia-like cells in the brain (PMID: 29226242; co-author)• Collaborated with laboratory colleagues on several HSC aging projects (PMID: 25274507, PMID: 23415915; co-author), as well as the first demonstration of CRISPR/Cas9-based ablation of clinically relevant genes in human hematopoietic cells (PMID: 25517468; co-author)(Laboratory of Dr. Derrick J. Rossi)

• Generated and comparatively analyzed transcriptomics data to identify hematopoietic stem cell (HSC)-specific transcription factors, which were then characterized using a variety of in vitro and in vivo functional assays (PMID: 24319662; co-first author)• Identified the transcription factor Zfp521 as a regulator of HSC pool size and MLL-AF9-mediated leukemic disease (PMID: 28615219; co-first author)• Identified Hlf as a key HSC regulator by demonstrating it could imbue progenitors with stem cell-like attributes• In collaboration with Dr. Timothy Springer laboratory, generated bone marrow-derived microglia for successful therapeutic treatment of a neurological disease caused by defective TGFβ signaling (PMID: 29909984; co-first author)• Utilized HSC transcription factor expertise in collaboration to reprogram hematopoietic cells to a stem cell fate (PMID: 24766805; co-author)• Utilized my HSC and microglia experience in collaboration to achieve engraftment of microglia-like cells in the brain (PMID: 29226242; co-author)• Collaborated with laboratory colleagues on several HSC aging projects (PMID: 25274507, PMID: 23415915; co-author), as well as the first demonstration of CRISPR/Cas9-based ablation of clinically relevant genes in human hematopoietic cells (PMID: 25517468; co-author)(Laboratory of Dr. Derrick J. Rossi)

• Utilized a microarray-based approach to identify HSC-specific regulators for possible therapeutic manipulation• Genes of interest were ectopically expressed or knocked-down within in vitro and in vivo functional assays for stem and progenitor cell activity• Studied the role of p57 in biological pathways unique to HSCs, including quiescence and self-renewal• Collaborated with laboratory colleagues on several HSC microenvironment projects (PMID: 18682243; co-author)• Collaborator for study of MLL-AF9-mediated leukemic disease (PMID: 28615219; co-first author)(Laboratory of Dr. David T. Scadden)

• Optimized transposon-mediated gene addition strategies for human gene therapy• Uncovered the extent of post-integrative silencing potential in transposon-mediated gene therapy approaches (PMID: 17938204; first author) while concurrently studying transposon integration site preferences (PMID: 15743807; co-author)(Laboratory of Dr. Mark A. Kay)

• Used forward genetic screens to identify and characterize regulators of autophagy (PMID: 10712513; co-author)• Studied the assembly of the yeast vacuolar proton-translocating ATPase (PMID: 9195975; co-author)(Laboratory of Dr. Daniel J. Klionsky)